SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) March 28, 2000
OPHIDIAN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 333-33219 39-1661164
(State, or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
5445 East Cheryl Parkway, Madison, Wisconsin 53711
(Address of principal executive offices)
Registrant's telephone number, including area code: (608) 271-0878
Not Applicable
(Former name or Former Address, if changed since last report)
<PAGE>
Item 5. Other Events.
See attached press release dated March 28, 2000,
filed herewith as Exhibit 99.1
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following is filed as an exhibit to
this Current Report on Form 8-K:
Exhibit Number Description of Exhibit
99.1 Press release dated March 28, 2000
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OPHIDIAN PHARMACEUTICALS, INC.
(Registrant)
Date: March 28, 2000 /s/ Donald L. Nevins
--------------------------
Donald L. Nevins
Vice President-Finance
<PAGE>
EXHIBIT INDEX
Exhibit
Number Description
99.1 Press release dated March 28, 2000
EXHIBIT 99.1
OPHIDIAN Pharmaceuticals, Inc.
5445 East Cheryl Parkway, Madison
Phone (608) 271-0878 FAX (608) 277-2395
FOR IMMEDIATE RELEASE
For more information, please contact:
Mr. Donald L. Nevins, Vice President, Finance
(608) 271-0878x108
E-mail: [email protected]
Ophidian Secures $1.3 Million from Patent Sale
MADISON, Wisconsin (March 28, 2000) - Ophidian
Pharmaceuticals, Inc. - NASDAQ [OPHD] & Pacific
Exchange [OPD] reported today that it has sold for $1.3
million five of its patent and patent applications from
its portfolio of over 90 issued or pending patents.
The patents sold are unrelated to Ophidian's core
development programs. Ophidian's Chief Executive
Officer, Douglas Stafford stated, "This sale represents
our ongoing efforts to realize value from our patent
estate while maintaining focus on our core technology
and development products." The company's lead products
are based on the oral delivery of antibodies from hen
eggs that are designed to treat infectious and
inflammatory diseases of the intestinal tract. The
company is currently conducting a Phase II clinical
trial of OPHD 001, a drug for the treatment of
Clostridium difficile associate disease. The company's
second oral antibody product, OPHD 002, for the
treatment of inflammatory bowel disease is in pre-
clinical development.
###
